Evidence-based skincare intelligence. The research, the science, and the stuff no one else is talking about.
A federal judge dismissed the Sephora “Clean at Sephora” class action in 2024 with a ruling that told you everything you need to know: the word means nothing, legally, and therefore cannot be false advertising. The FDA’s December 2025 PFAS report then made the meaninglessness measurable — 76% of the top cosmetic PFAS have safety profiles the agency could not determine.
Behind the aquarium-branded marketing sits a 40-year-old European drug with a mapped adenosine A2A receptor mechanism, extensive clinical evidence, and Korean-scale manufacturing. Also: none of it is FDA-approved. The gap between the science and the U.S. regulatory posture is the real story.
A 2025 Unilever study in the British Journal of Dermatology found that people who appear older than their chronological age carry measurably different bacteria on their faces — higher Acinetobacter, more fragile microbial networks. The mechanism is not acne. It is an ecosystem aging in parallel with the skin underneath it.
A measurable population of “zombie” cells builds up in your skin with age and actively sabotages the tissue around them. Senolytics are the first ingredient class that removes them. The first cosmetic senolytic shipped in 2024. Most consumers have not noticed.
The first new UV filter approved in U.S. sunscreen in 25 years is finally on the FDA’s desk. Europe has had it since 2000. Why the regulatory gap mattered, what bemotrizinol actually does, and which brands will move first.
10x more bioavailable than retinol, one conversion step from the active form, and mounting clinical data showing it outperforms — with less irritation. Why the skincare industry buried its best retinoid.
Zinc oxide doesn't "sit on top and reflect UV like a mirror." It absorbs 95% of the UV it blocks — the same mechanism as chemical sunscreen. Photobiologists have known this for decades.
Search interest is up 557%. The clinical data is genuinely promising. But the FDA has zero approved exosome products, and the gap between the science and what's being sold is enormous.
The barrier-care trend has produced a documented rise in irritant contact dermatitis. The real barrier science — ceramide ratios, microbiome layers, postbiotic signaling — is almost absent from the conversation.